- Home
- RLAY vs ESNT Comparison
RLAY vs ESNT Comparison
Compare RLAY & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- ESNT
- Stock Information
- Founded
- RLAY 2015
- ESNT 2008
- Country
- RLAY United States
- ESNT Bermuda
- Employees
- RLAY N/A
- ESNT N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- ESNT Property-Casualty Insurers
- Sector
- RLAY Health Care
- ESNT Finance
- Exchange
- RLAY Nasdaq
- ESNT Nasdaq
- Market Cap
- RLAY 576.1M
- ESNT N/A
- IPO Year
- RLAY 2020
- ESNT 2013
- Fundamental
- Price
- RLAY $3.60
- ESNT $55.99
- Analyst Decision
- RLAY Strong Buy
- ESNT Buy
- Analyst Count
- RLAY 11
- ESNT 7
- Target Price
- RLAY $18.40
- ESNT $63.71
- AVG Volume (30 Days)
- RLAY 1.5M
- ESNT 741.5K
- Earning Date
- RLAY 08-05-2025
- ESNT 08-01-2025
- Dividend Yield
- RLAY N/A
- ESNT 2.21%
- EPS Growth
- RLAY N/A
- ESNT 3.49
- EPS
- RLAY N/A
- ESNT 6.84
- Revenue
- RLAY $7,679,000.00
- ESNT $1,262,105,000.00
- Revenue This Year
- RLAY $17.59
- ESNT $5.40
- Revenue Next Year
- RLAY N/A
- ESNT $3.66
- P/E Ratio
- RLAY N/A
- ESNT $8.19
- Revenue Growth
- RLAY N/A
- ESNT 9.57
- 52 Week Low
- RLAY $1.78
- ESNT $51.61
- 52 Week High
- RLAY $10.72
- ESNT $65.34
- Technical
- Relative Strength Index (RSI)
- RLAY 57.25
- ESNT 34.11
- Support Level
- RLAY $3.50
- ESNT $60.34
- Resistance Level
- RLAY $3.86
- ESNT $61.94
- Average True Range (ATR)
- RLAY 0.18
- ESNT 1.06
- MACD
- RLAY 0.02
- ESNT -0.55
- Stochastic Oscillator
- RLAY 65.79
- ESNT 2.90
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).